Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1994 Jan;39(1):27–33. doi: 10.1007/BF01517177

Characterization and purification of a mycoplasma membrane-derived macrophage-activating factor

Steve Caplan 1,✉, Ruth Gallily 1, Yechezkel Barenholz 2
PMCID: PMC11037937  PMID: 8044823

Abstract

A highly hydrophobic component derived from the membrane ofMycoplasma capricolum has been characterized, purified and assessed for its ability to activate macrophages to tumor cytotoxicity. Initially, crude membranes were evaluated for their solubility in a wide range of solvents. Despite differential solubility in the various solvents, the mycoplasma membranes retained their ability to potentiate macrophage tumor cytotoxicity. Mycoplasma membranes were further characterized by appraising their macrophage-activating ability subsequent to various chemical treatments: cleavage of ester and thioester bonds, oxidation of vicinal hydroxyl groups, and exposure to a broad range of pH. Only strong alkaline treatment (pH>12) caused a reduction in mycoplasma membrane activity: all other chemical treatments were inconsequential. With potential therapeutic applications in mind, mycoplasma membranes were subjected to various physical treatments including heating, freezing/thawing, sonication, lyophilization and storage. The ability of the membranes to induce macrophage activation was stably maintained following all these treatments. Purification of membranes was initiated by a chloroform/methanol lipid extraction. Macrophage-activating ability was found predominantly in the interphase. Proteolytic cleavage with trypsin increased specific activity at least sixfold. Trypsinized fractions were solubilized in 2-chloroethanol and gel filtration was performed on a hydroxylated Sephadex LH-60 column. The active fraction from this column had a further tenfold increase in specific activity. Subsequent rounds of reverse-phase HPLC on this fraction yielded three to four peaks absorbing at 280 nm, of which only one had macrophage-activating ability.

Key words: Macrophage activation, Tumor cytotoxicity, Mycoplasma membrane, Purification

References

  • 1.Fidler IJ. Macrophages and metastasis — a biological approach to cancer therapy: presidential address. Cancer Res. 1985;45:4714–4726. [PubMed] [Google Scholar]
  • 2.Fidler IJ, Raz A, Fogler WE, et al. The design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res. 1980;40:4460–4466. [PubMed] [Google Scholar]
  • 3.Schroit AJ, Fidler IJ. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res. 1982;42:161–167. [PubMed] [Google Scholar]
  • 4.Key ME, Talmadge JE, Fogler WE, et al. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J Natl Cancer Inst. 1982;69:1189–1198. [PubMed] [Google Scholar]
  • 5.Sanguedolce MV, Capo C, Bongrande P, Mege JL. Zymosan-stimulated tumor necrosis factor-α production by human monocytes. J Immunol. 1992;148:2229–2236. [PubMed] [Google Scholar]
  • 6.Utsugi T, Nii A, Fan D, Pak CC, Denkins Y, Van Hoogevest P, Fidler IJ. Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages. Cancer Immunol Immunother. 1991;33:285–292. doi: 10.1007/BF01756592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Nii A, Utsugi T, Fan D, et al. Optimization of the liposomes encapsulating a new lipopeptide CGP 31362 for efficient activation of tumoricidal properties in monocytes and macrophages. J Immunother. 1991;10:236–246. doi: 10.1097/00002371-199108000-00002. [DOI] [PubMed] [Google Scholar]
  • 8.Lowenstein J, Rottem S, Gallily R. Induction of macrophage-mediated cytolysis of neoplastic cells by mycoplasmas. Cell Immunol. 1983;77:290–297. doi: 10.1016/0008-8749(83)90029-1. [DOI] [PubMed] [Google Scholar]
  • 9.Gallily R, Sher T, Ben Av P, Lowenstein J. Tumor necrosis factor as a mediator ofMycoplasma orale tumor cell lysis by macrophages. Cell Immunol. 1989;121:146–151. doi: 10.1016/0008-8749(89)90012-9. [DOI] [PubMed] [Google Scholar]
  • 10.Sher T, Yamin A, Matzliach M, Rottem S, Gallily R. Partial biochemical characterization ofSpiroplasma membrane component inducing tumor necrosis factor alpha. Anticancer Drugs. 1990;1:83–87. doi: 10.1097/00001813-199010000-00014. [DOI] [PubMed] [Google Scholar]
  • 11.Barile MT, Razin S, Tully JG, Whitcomb RF. The mycoplasmas. London: Academic Press; 1979. [Google Scholar]
  • 12.Smith PF. Antigenic character of membrane lipoglycans from Mollicutes: a review. Isr J Med Sci. 1987;23:448–452. [PubMed] [Google Scholar]
  • 13.Sher T, Rottem S, Gallily R. Mycoplasma capricolum membranes induce tumor necrosis factor by a mechanism different from that of lipopolysaccharide. Cancer Immunol Immunother. 1990;31:86–92. doi: 10.1007/BF01742371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Razin S, Rottem S. Techniques for the manipulation of mycoplasma membranes. In: Maddy AH, editor. Biochemical analysis of membranes. London: Chapman & Hall; 1970. [Google Scholar]
  • 15.Minamide LS, Bamburg JR. A filter paper dye-binding assay for quantitative determination of protein without interference from reducing agents or detergents. Anal Biochem. 1990;190:66–70. doi: 10.1016/0003-2697(90)90134-u. [DOI] [PubMed] [Google Scholar]
  • 16.Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–917. doi: 10.1139/o59-099. [DOI] [PubMed] [Google Scholar]
  • 17.Hashimoto Y. Action of enzymes on mucin. Ann NY Acad Sci. 1963;106:233–246. doi: 10.1111/j.1749-6632.1963.tb16641.x. [DOI] [PubMed] [Google Scholar]
  • 18.Sandermann H, Strominger JL. Purification and properties of C55-isoprenoid alcohol phosphokinase fromStaphylococcus aureus . J Biol Chem. 1972;247:5123–5131. [PubMed] [Google Scholar]
  • 19.Zahler P, Weibel ER. Reconstitution of membranes by recombining proteins and lipids derived from erythrocyte stroma. Biophys Biochim Acta. 1970;219:320–338. doi: 10.1016/0005-2736(70)90210-5. [DOI] [PubMed] [Google Scholar]
  • 20.Zahler PH, Wallach DFH. Isolation of lipid-free plasma membrane proteins by gel filtration on Sephadex LH-20 using 2-chloroethanol-water as a solvent. Biophys Biochim Acta. 1967;135:371–374. doi: 10.1016/0005-2736(67)90135-6. [DOI] [PubMed] [Google Scholar]
  • 21.Tower D, Glaser L. Protein fatty acid acylation: enzymatic synthesis of anN-myristoylglycyl peptide. Proc Natl Acad Sci USA. 1986;83:2812–2816. doi: 10.1073/pnas.83.9.2812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Gamberg GG, Hayry P, Andersson LC. Characterization of surface glycoproteins of mouse lymphoid cells. J Cell Biol. 1976;68:642–653. doi: 10.1083/jcb.68.3.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Andreesen R, Scheibenbogen C, Brugger W, et al. Adoptive transter of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res. 1990;50:7450–7456. [PubMed] [Google Scholar]
  • 24.MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst. 1989;81:935–938. doi: 10.1093/jnci/81.12.935. [DOI] [PubMed] [Google Scholar]
  • 25.Fidler IJ, Fogler WE, Brownbill AF, et al. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide. J Immunol. 1987;138:4509–4514. [PubMed] [Google Scholar]
  • 26.Murray JL, Kleinerman ES, Cunningham JE, et al. Phase I trial of liposomal muramyl tripeptide phospatidyl ethanolamine in cancer patients. J Clin Oncol. 1989;7:1915–1925. doi: 10.1200/JCO.1989.7.12.1915. [DOI] [PubMed] [Google Scholar]
  • 27.Bate CAW, Taverne J, Playfair JHL. Detoxified exoantigens and phosphatidylinositol derivatives inhibit tumor necrosis factor induction by malarial exoantigens. Infect Immun. 1992;60:1894–1901. doi: 10.1128/iai.60.5.1894-1901.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ruuth E, Praz F. Interactions between mycoplasmas and the immune system. Immunol Rev. 1989;112:133–160. doi: 10.1111/j.1600-065x.1989.tb00556.x. [DOI] [PubMed] [Google Scholar]
  • 29.Takema M, Oka S, Uno K, Nakamura S, Arita H, Tawara K, Inaba K, Muramatsu S. Macrophage activating factor extracted from mycoplasmas. Cancer Immunol Immunother. 1991;33:39–44. doi: 10.1007/BF01742526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Sugama K, Kuwono K, Furukawa M, et al. Mycoplasmas induce transcription and production of tumor necrosis in a monocyte cell line, THP-1, by a protein kinase c-independent pathway. Infect Immun. 1990;58:3564–3567. doi: 10.1128/iai.58.11.3564-3567.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES